To research the nairovirus, Crimean-Congo hemorrhagic fever, a tick-borne viral disease, especially common in East and West Africa. With mortality rates as high as 80 percent and with no FDA approved vaccines or therapeutics, Crimean-Congo hemorrhagic fever is considered a dangerous pathogen and a serious bioterrorism threat. The project will expand the knowledge of the ovarian tumor protease domain of the nairovirus to inform control measures and vaccine development.